Eli Lilly and Company $LLY Shares Sold by Laurel Wealth Advisors LLC

Laurel Wealth Advisors LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 99.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 15,013 shares of the company’s stock after selling 11,537,323 shares during the quarter. Eli Lilly and Company comprises about 1.6% of Laurel Wealth Advisors LLC’s investment portfolio, making the stock its 16th biggest position. Laurel Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $11,455,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Ted Buchan & Co boosted its position in shares of Eli Lilly and Company by 5.2% during the 3rd quarter. Ted Buchan & Co now owns 3,922 shares of the company’s stock worth $2,992,000 after purchasing an additional 195 shares during the period. Accent Capital Management LLC lifted its stake in Eli Lilly and Company by 1.2% during the third quarter. Accent Capital Management LLC now owns 5,814 shares of the company’s stock worth $4,436,000 after purchasing an additional 67 shares in the last quarter. River Wealth Advisors LLC boosted its position in shares of Eli Lilly and Company by 10.9% during the third quarter. River Wealth Advisors LLC now owns 12,316 shares of the company’s stock worth $9,397,000 after buying an additional 1,213 shares during the period. Bedell Frazier Investment Counselling LLC boosted its position in shares of Eli Lilly and Company by 2.1% during the third quarter. Bedell Frazier Investment Counselling LLC now owns 9,839 shares of the company’s stock worth $7,507,000 after buying an additional 198 shares during the period. Finally, New Age Alpha Advisors LLC grew its stake in shares of Eli Lilly and Company by 15.2% in the third quarter. New Age Alpha Advisors LLC now owns 12,550 shares of the company’s stock valued at $9,576,000 after buying an additional 1,658 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Topline ACHIEVE‑3 results for type 2 diabetes showed meaningful A1C and weight benefits for Lilly’s oral GLP‑1 in a head‑to‑head setting, reinforcing the drug’s commercial and regulatory potential. Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes
• Positive Sentiment: Detailed Phase 3/Lancet results show orforglipron outperformed oral semaglutide on A1C and weight in ACHIEVE‑3, strengthening Lilly’s case for market share and supporting upcoming regulatory timelines (U.S. obesity decision possible in Q2). Orforglipron Lancet results PR Newswire
• Positive Sentiment: CHMP issued a positive opinion for expanded EU use of Olumiant (baricitinib) in adolescents with severe alopecia areata — a near‑term regulatory win that expands labeled indications and revenue opportunities in Europe. Olumiant CHMP positive opinion PR Newswire
• Positive Sentiment: RBC Capital initiated coverage with an Outperform and $1,250 PT, signaling institutional confidence in Lilly’s obesity leadership; coupled with recent price‑target increases from other shops, this boosts investor conviction. RBC Capital initiates Eli Lilly
• Positive Sentiment: High‑profile media/TV endorsements (e.g., Jim Cramer recommending Lilly over Novo Nordisk) are supportive for retail flows and sentiment toward LLY. Jim Cramer Recommends Eli Lilly
• Neutral Sentiment: Reuters published additional trial safety data giving a more detailed picture of side effects — useful context for regulators and investors but not a clear negative or positive on balance. Reuters: additional data on weight-loss pill
• Neutral Sentiment: Health‑care stocks broadly moved higher today, which can amplify sector leaders’ moves but may reflect macro/flow dynamics rather than company‑specific fundamentals. Sector Update: Health Care Stocks Higher
• Negative Sentiment: Smaller rivals (e.g., Viking Therapeutics) and other entrants remain active in the obesity space — a potential long‑term competitive risk that could pressure pricing and market share over time. Viking Therapeutics profile

Analysts Set New Price Targets

Several research firms recently issued reports on LLY. Rothschild & Co Redburn increased their target price on Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a research note on Monday, January 26th. Scotiabank reissued an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Berenberg Bank upped their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. Finally, HSBC reissued a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,229.59.

Eli Lilly and Company Trading Up 2.8%

NYSE LLY opened at $1,050.39 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The stock has a market capitalization of $990.90 billion, a PE ratio of 45.77, a price-to-earnings-growth ratio of 1.22 and a beta of 0.39. The firm has a 50 day moving average of $1,053.15 and a two-hundred day moving average of $930.04.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same period in the previous year, the company earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is currently 30.15%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.